|
|
| Type |
Symposium |
| Area |
Recent Trends in Drug Discovery and Technology |
| Room No. |
404호 |
| Time |
THU 13:30-: |
| Code |
MEDI-1 |
| Subject |
Versatile strategy for controlling the specificity and activity of engineered T cells |
| Authors |
김찬혁
한국과학기술원 생명과학과, Korea |
| Abstract |
Cancer immunotherapy has been drawing growing attention as a novel promising therapeutic modality for cancer. Unlike conventional chemo- or radiotherapy, immunotherapy treats cancer by unleashing the suppressed activity of the patient’s own immune system and harnessing its power to fight cancer, to achieve robust anti-tumor responses while minimizing collateral damages to normal tissues. Among several immunotherapeutic approaches, second generation CD19-targeting chimeric antigen receptor (CAR) T cells engineered with costimulatory signaling domains have generated unprecedented anti-leukemic responses in patients with refractory B-cell leukemia. In light of their clinical promise, there has been an explosion of interest in CAR-T cells for cancer immunotherapy, especially for the treatment of relapsed, refractory malignancies. However, the inability to control the activity of this potent “live” drug has resulted in severe treatment related toxicities and the constraint in targeting more than one antigen have limited its general application. In this talk, I will discuss our recent research efforts focusing on addressing these limitations of current CAR-T therapy. |
| E-mail |
kimchanhyuk@kaist.ac.kr |
|
119th General Meeting of the KCS